James Breitmeyer MD PhD

PubMed

• 3 citations
  Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
  Paul A Meyers, Noah Federman, Najat Daw, Peter M Anderson, Lara E Davis
  Journal of Clinical Oncology. 2024-11-01
• 2 citations
  Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
  Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
  Breast Cancer Research. 2024-03-13
• 3 citations
  A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
  Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
  Breast Cancer Research. 2024-02-26

Journal Articles

• Antitumor efficacy of poxvirus-based active immunotherapy alone and in combination with subtherapeutic dosing with immune checkpoint inhibitors  
  Foy SP, Rountree RB, Cote J, Gordon E, Trent E, Franzusoff AJ, Breitmeyer JB, Mandl SJ, J Clin Oncol, 1/1/2014
• PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action  
  Mandl SJ, Rountree RB, Owen RB, dela Cruz T, Hwang O, Paranjpe G, Enstrom A, Franzusoff AJ, Goessl C, Breitmeyer JB, J Clin Oncol, 1/1/2014
• Intravenous Acetaminophen for Pain after Major Orthopedic Surgery: An Expanded Analysis  
  Sinatra RS, Jahr JS, Reynolds L, Groudine SB, Royal MA, Breitmeyer JB, Viscusi ER, Pain Practice, 1/1/2012
• A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever  
  Peacock WF, Breitmeyer J, Pan C, Smith WB, Royal MA, Acad. Emerg. Med. Acad Emerg Med, 1/1/2011
• Childhood asthma and use during pregnancy of acetaminophen: a critical review  
  Scialli AR, Ang R, Breitmeyer J, Royal MA, Reprod Toxicol, 1/1/2010
• A randomized, double-blind, placebo-controlled, multi-center, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdomi...  
  Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK, Clin Ther, 1/1/2010
•  
  Tutuncu Z, Boyle D, Breitmeyer J, Kavanaugh A, ACR, 1/1/2006
• A Dose Escalation, Open-Label, Phase I/II Study of AME-527, A Novel Anti-TNF Monoclonal Antibody (mAb) in Subjects with Active Rheumatoid Arthritis  
  Tutuncu Z, Boyle D, Lee S, Hallinan J, Weber J, Vasserot A, Breitmeyer J, Kavanaugh A, ACR, 1/1/2005
• AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function  
  Breitmeyer, JB; Campbell, MA; Allan, B; Marquis, D; Ondek, B; Watkins, J, J Immunother, 1/1/2004
• Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretrovira...  
  Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O’Brien F, Svanberg E, J Acquir Immune Defic Syndr, 1/1/2004
• Hypogonadism is uncommon in men with AIDS-associated wasting  
  Gertner JM, BreitmeyerJB, Kennedy SM, ICAC, 1/1/1998
• Recombinant human growth hormone in patients with HIV-associated wasting A randomized, placebo-controlled trial  
  Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, BreitmeyerJB, Ann Intern Med, 1/1/1996
• Clinical relevance of DEXA-determined lean body mass in patients with AIDS wasting  
  Pierson R, Wang J, Landy H, BreitmeyerJ, Kotler D, Int Conf AIDS, 1/1/1996
• A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting  
  Berger DS, LaMarca A, Landy H, Kauffman RS, BreitmeyerJ, Int Conf AIDS, 1/1/1996
• Immunomodulatory effects of mammalian cell-derived human recombinant growth hormone (r-hGH[m]) in patients with AIDS wasting  
  Denny TN, Landy H, BreitmeyerJB, 3rd Conf Retro and Opportun Infect, 1/1/1996
• Recombinant, mammalian cell-derived human growth hormone (r- hGH[m]) does not increase HIV replication in vitro or in treated patients  
  Daar ES, Polsky B, Mellors J, BreitmeyerJ, 3rd Conf Retro and Opportun Infect, 1/1/1996
• Effect of continuous growth hormone therapy on lean body mass (LBM) and AIDS-defining events in HIV-associated wasting (HIV-W)  
  Daar ES, LaMarca A, Schambelan M, Grunfeld C, Mulligan K, BreitmeyerJ, 3rd Conf Retro and Opportun Infect, 1/1/1996
• Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer  
  Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, BreitmeyerJ, Alger ME, Borden EC, J. Interferon & Cytokine Research, 1/1/1996
• Recombinant human growth hormone (rhGH) increases lean body mass (LBM) and improves functional performance in patients with HIV-associated wasting  
  Schambelan M, Mulligan K, Grunfeld C, Daar E, Lamarca A, BreitmeyerJ, Natl Conf Hum Retroviruses Relat Infect, 1/1/1995
• Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin 6 before and after cytotoxic chemotherapy  
  Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, Von Hoff DD, Vaickus L, Drechsler D, Borden EC, Galazka A, BreitmeyerJB, Abdul-Ah..., Ann NY Acad Sci, 1/1/1995
• Growth hormone therapy of AIDS wasting  
  Schambelan M, LaMarca A, Mulligan K, Grunfeld C, Kennedy S, Int Conf AIDS, 1/1/1994
• Human recombinant interleukin-6 activated peripheral blood monocytes in vitro and in vivo  
  Witt PL, Keever C, Ritch PS, Truitt RL, Grossberg SE. BreitmeyerJB, Proc Annu Meet Am Assoc Cancer Res, 1/1/1994
• Phase I trial of recombinant beta-interferon (r-IFNbeta; R-FRONE) and radiation therapy (RT) for non-small cell lung cancer (NSCLC)  
  Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, BreitmeyerJ, Alger ME, Borden EC, Proc Annu Meet Am Soc Clin Oncol, 1/1/1994
• Genetic reconstitution of the T cell receptor alpha-beta heterodimer restores the association of CD3-zeta 2 with the T cell receptor/CD3 complex  
  Blumberg RS, Sancho J, Ley SC, McDermott FV, Tan K-N, BreitmeyerJ and Terhorst C, Eur J Immunology, 1/1/1991
• Assembly and function of the T cell antigen receptor: Requirement of either the lysine or arginine residues in the transmembrane region of the alpha chain  
  Blumberg RS, Alarcon B, Sancho J, McDermott FV, Lopez P, BreitmeyerJB and Terhorst C, J Biol Chem, 1/1/1990
• Join now to see all

Books/Book Chapters

• Immunotherapy of breast cancer 
  BreitmeyerJB1992
• Breast Diseases 
  Chapter: Immunological aspects of breast tumor biology 
  BreitmeyerJBEditors: Harris J, Hellman S, Henderson IC and Kinne D.J B Lippincott, Pholadelphia, PA1991
• Breast Diseases 
  Chapter: New forms of systemic therapy of metastatic breast cancer including immunotherapy 
  Breast DiseasesEditors: Harris J, Hellman S, Henderson IC and Kinne D.J B Lippincott, Philadelphia, PA1990
• Cellular Basis of Immune Modulation 
  Chapter: CD4 and CD8 molecules influence T cell receptor function: Evidence from monoclonal antibody binding studies 
  BreitmeyerJB, Anderson PA, Daley JF and Schlossman SFEditors: Kaplan JG, Green DR and Bleackley RC.A.R. Liss, Inc., New York, NY1989
• Leukocyte Typing III 
  Chapter: T-cell calcium mobilization by T11 (CD2) antibodies requires cell surface expression of the antigen receptor complex 
  Breitmeyer J, Daley J, Levine H and Schlossman SEditors: Oxford University Press.1987
• Washington University Manual of Medical Therapeutics 
  Chapter: Anemia and transfusion therapy 
  Page 284 - 298BreitmeyerJBEditors: Orland MJ and Saltman RJ.Little, Brown and Co., Boston, MA1986
• Join now to see all

Abstracts/Posters

• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  James B. Breitmeyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  James B. Breitmeyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of 7 day continuous infusion
  Nadler L, BreitmeyerJ, Grossbard M, Spector N, Rabinowe S, Coral F, Ritz J, Schlossman S, Blood, 1/1/1990

Lectures

• Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of 7 day continuous infusion 
  1/4/1990
• Inhibition of breast cancer cell growth in vitro by a new monoclonal antibody, BC78 
  Las Vegas, NV - 1/5/1988